Welcome to our dedicated page for TenX Keane Acquisition Right news (Ticker: TENKR), a resource for investors and traders seeking the latest updates and insights on TenX Keane Acquisition Right stock.
TenX Keane Acquisition Right (TENKR) is a company specializing in acquisitions and mergers within the technology sector. With a focus on identifying undervalued assets, they aim to enhance shareholder value through strategic partnerships and investments. Recent achievements include successful acquisitions of several promising startups and partnerships with industry leaders. Their current projects involve expanding into new markets and developing innovative technologies to maintain a competitive edge. Financially, the company has shown steady growth and profitability, attracting investors looking for long-term potential.
TenX Keane Acquisition (Nasdaq: TENKU) faced a trading halt on August 7, 2024, due to additional information requested by Nasdaq following unusual trading activity. The company is working with Nasdaq to lift the halt. Meanwhile, TenX shareholders approved the merger with Citius Oncology on August 2, 2024. The post-merger entity is expected to trade as Citius Oncology, Inc. (CTOR) on Nasdaq.
In a related development, Citius Pharmaceuticals (Nasdaq: CTXR) announced FDA approval for LYMPHIR™, a treatment for relapsed or refractory cutaneous T-cell lymphoma. TenX and Citius Pharma are progressing towards closing the business combination in the near future.
TenX Keane Acquisition shareholders have approved the merger with Citius Pharmaceuticals' oncology subsidiary to form Citius Oncology, Inc. The vote took place at an extraordinary general meeting on August 2, 2024. The newly combined company is expected to trade on Nasdaq under the Citius Oncology name. This merger aims to support the commercialization of LYMPHIR, pending approval, and explore additional oncology assets. The transaction is anticipated to provide Citius Oncology with improved access to public equity markets. Subject to closing conditions, the merger is expected to be completed in the coming weeks. This strategic move positions Citius Oncology to advance its oncology pipeline and potentially strengthen its market presence in the biopharmaceutical sector.
TenX Keane Acquisition (NASDAQ:TENKU) announced the closing of its initial public offering (IPO) of 6,600,000 units at an offering price of $10.00 per unit, generating $66,000,000 in gross proceeds. The IPO included a partial exercise of the underwriter's over-allotment option for 600,000 units. Each unit consists of one ordinary share and one right, with rights entitling holders to receive two-tenths of one share upon the initial business combination. The units began trading on NASDAQ under the symbol TENKU on October 14, 2022.
TenX Keane Acquisition has successfully priced its initial public offering (IPO) at $10.00 per unit, totaling 6,000,000 units. Each unit includes one ordinary share and a right to receive two-tenths of one ordinary share upon completing the Company's initial business combination. Trading under the ticker symbol TENKU begins on October 14, 2022, on the Nasdaq Global Market. The underwriter, Maxim Group LLC, has a 45-day option to purchase an additional 900,000 units. The offering is slated to close on October 18, 2022, pending customary closing conditions.
FAQ
What is the current stock price of TenX Keane Acquisition Right (TENKR)?
What is TenX Keane Acquisition Right (TENKR) known for?
What is the focus of TenX Keane Acquisition Right?
What are some recent achievements of TenX Keane Acquisition Right?
What are the current projects of TenX Keane Acquisition Right?
How is the financial condition of TenX Keane Acquisition Right?
What sectors does TenX Keane Acquisition Right operate in?
What sets TenX Keane Acquisition Right apart from competitors?
Is TenX Keane Acquisition Right a publicly traded company?
What is the long-term goal of TenX Keane Acquisition Right?
How can investors benefit from TenX Keane Acquisition Right?
